Natera’s (NTRA) Buy Rating Reaffirmed at Robert W. Baird
Natera, Inc. (NASDAQ:NTRA)‘s stock had its “buy” rating reaffirmed by equities research analysts at Robert W. Baird in a research report issued to clients and investors on Tuesday.
Several other equities research analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Natera from a “sell” rating to a “buy” rating and set a $9.25 target price on the stock in a research note on Thursday, August 10th. ValuEngine raised shares of Natera from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 10th. Cowen and Company reissued a “buy” rating and issued a $14.00 target price on shares of Natera in a research note on Friday, September 1st. BidaskClub downgraded shares of Natera from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Finally, Morgan Stanley reduced their target price on shares of Natera from $18.00 to $13.00 and set an “overweight” rating on the stock in a research note on Monday, August 7th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $16.20.
Shares of Natera (NASDAQ:NTRA) traded down 1.88% during trading on Tuesday, reaching $12.52. 104,300 shares of the company were exchanged. The company’s market capitalization is $666.35 million. The stock’s 50 day moving average is $13.06 and its 200 day moving average is $13.06. Natera has a 1-year low of $7.35 and a 1-year high of $14.76.
Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, August 8th. The medical research company reported ($0.52) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.52). Natera had a negative net margin of 62.64% and a negative return on equity of 137.46%. The business had revenue of $53.60 million during the quarter, compared to analyst estimates of $50.57 million. During the same quarter last year, the business earned ($0.46) earnings per share. Natera’s quarterly revenue was up 3.1% compared to the same quarter last year. Equities analysts anticipate that Natera will post ($2.03) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/24/nateras-ntra-buy-rating-reaffirmed-at-robert-w-baird.html.
In related news, insider Jonathan Sheena sold 120,000 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $12.54, for a total value of $1,504,800.00. Following the transaction, the insider now owns 533,208 shares of the company’s stock, valued at approximately $6,686,428.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 12.57% of the company’s stock.
A number of institutional investors have recently modified their holdings of NTRA. Virtu KCG Holdings LLC bought a new position in Natera during the 2nd quarter worth about $126,000. American International Group Inc. grew its holdings in Natera by 7.1% during the 1st quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock worth $142,000 after acquiring an additional 1,068 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Natera by 1.2% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 16,118 shares of the medical research company’s stock worth $143,000 after acquiring an additional 194 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in Natera during the 2nd quarter worth about $151,000. Finally, Goldman Sachs Group Inc. grew its holdings in Natera by 45.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 17,386 shares of the medical research company’s stock worth $154,000 after acquiring an additional 5,417 shares in the last quarter. Institutional investors own 59.74% of the company’s stock.
Natera Company Profile
Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.